Holland & Hart represented Vescent Technologies, Inc. on the matter. Vescent Technologies, Inc., a developer and manufacturer of novel electro-optic and precision laser technologies, announced its...
You must be a Standard 1 Year member to access this content.
TozziniFreire Advogados advised DFB Brasil Participações Ltda. on the deal. The transaction consisted in a private placement of common shares issued by Ownerinc Developers S.A. in...
You must be a Standard 1 Year member to access this content.
Skadden advised Becton, Dickinson and Company, while Sullivan & Cromwell advised the underwriters in the offering. Becton, Dickinson and Company executed its $1.175b offering of U.S....
You must be a Standard 1 Year member to access this content.
Skadden advised Becton, Dickinson and Company, while Sullivan & Cromwell advised the underwriters in the offering. Becton, Dickinson and Company executed its €750 million offering of euro...
You must be a Standard 1 Year member to access this content.
Sullivan & Worcester advised Brenmiller Energy on the offering. Brenmiller Energy ($BNRG) Ltd., a global leader in thermal energy storage (TES), announced its $4 million public...
You must be a Standard 1 Year member to access this content.
Cuatrecasas represented Transportadora de Gas Internacional in the transaction. Bancolombia and BBVA granted Transportadora de Gas Internacional (TGI) a financing in the amount of COP $1.5 billion, for...
You must be a Standard 1 Year member to access this content.
Ashurst acted for Strategic IDC Limited as a borrower on the deal. Strategic IDC Limited acted as a borrower in a HK$5,600 million syndicated sustainability-linked loan,...
You must be a Standard 1 Year member to access this content.
Goodwin represented Myrobalan Therapeutics on the matter. Myrobalan Therapeutics announced its $24 million Series A financing. The round was led by Co-win Ventures, with participation from...
You must be a Standard 1 Year member to access this content.
Paul Hastings advised Kyverna Therapeutics in connection with the company’s upsized initial public offering. Kyverna Therapeutics, Inc., a patient-centered clinical-stage biopharmaceutical company focused on developing cell...
You must be a Standard 1 Year member to access this content.
